| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | lenvatinib | CTRPv2 | pan-cancer | AAC | -0.029 | 0.4 |
| mRNA | BRD-K37390332 | CTRPv2 | pan-cancer | AAC | 0.031 | 0.4 |
| mRNA | Imatinib | CTRPv2 | pan-cancer | AAC | -0.029 | 0.4 |
| mRNA | RG-108 | CTRPv2 | pan-cancer | AAC | 0.028 | 0.4 |
| mRNA | temsirolimus | CTRPv2 | pan-cancer | AAC | -0.037 | 0.4 |
| mRNA | NVP-BSK805 | CTRPv2 | pan-cancer | AAC | -0.027 | 0.4 |
| mRNA | BRD-K04800985 | CTRPv2 | pan-cancer | AAC | -0.029 | 0.4 |
| mRNA | tivantinib | CTRPv2 | pan-cancer | AAC | 0.035 | 0.4 |
| mRNA | SMER-3 | CTRPv2 | pan-cancer | AAC | -0.03 | 0.4 |
| mRNA | navitoclax:MST-312 (1:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.028 | 0.4 |